128 related articles for article (PubMed ID: 29396851)
1. Medications that relax the lower oesophageal sphincter and risk of oesophageal cancer: An analysis of two independent population-based databases.
Spence AD; Busby J; Murchie P; Kunzmann AT; McMenamin ÚC; Coleman HG; Johnston BT; O'Rorke MA; Murray LJ; Iversen L; Lee AJ; Cardwell CR
Int J Cancer; 2018 Jul; 143(1):22-31. PubMed ID: 29396851
[TBL] [Abstract][Full Text] [Related]
2. Barrett's esophagus and medications that relax the lower esophageal sphincter.
Corley DA; Levin TR; Habel LA; Buffler PA
Am J Gastroenterol; 2006 May; 101(5):937-44. PubMed ID: 16573773
[TBL] [Abstract][Full Text] [Related]
3. Non-steroidal anti-inflammatory drugs, lower oesophageal sphincter-relaxing drugs and oesophageal cancer. A case-control study.
Ranka S; Gee JM; Johnson IT; Skinner J; Hart AR; Rhodes M
Digestion; 2006; 74(2):109-15. PubMed ID: 17167266
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis: risk of esophageal adenocarcinoma with medications which relax the lower esophageal sphincter.
Alexandre L; Broughton T; Loke Y; Beales IL
Dis Esophagus; 2012 Aug; 25(6):535-44. PubMed ID: 22129441
[TBL] [Abstract][Full Text] [Related]
5. The effect of medications which cause inflammation of the gastro-oesophageal tract on cancer risk: a nested case-control study of routine Scottish data.
Busby J; Murchie P; Murray L; Iversen L; Lee AJ; Spence A; Watson MC; Cardwell CR
Int J Cancer; 2017 Apr; 140(8):1828-1835. PubMed ID: 28120338
[TBL] [Abstract][Full Text] [Related]
6. Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux.
Vaughan TL; Farrow DC; Hansten PD; Chow WH; Gammon MD; Risch HA; Stanford JL; Schoenberg JB; Mayne ST; Rotterdam H; Dubrow R; Ahsan H; West AB; Blot WJ; Fraumeni JF
Cancer Epidemiol Biomarkers Prev; 1998 Sep; 7(9):749-56. PubMed ID: 9752982
[TBL] [Abstract][Full Text] [Related]
7. The role of 5α-reductase inhibitors in gastro-oesophageal cancer risk: A nested case-control study.
Busby J; Karasneh R; Murchie P; McMenamin Ú; Gadalla SM; Camargo MC; Iversen L; Lee AJ; Spence AD; Cardwell CR
Pharmacoepidemiol Drug Saf; 2020 Jan; 29(1):48-56. PubMed ID: 31713940
[TBL] [Abstract][Full Text] [Related]
8. Risk of Barrett's oesophagus, oesophageal adenocarcinoma and reflux oesophagitis and the use of nitrates and asthma medications.
Ladanchuk TC; Johnston BT; Murray LJ; Anderson LA;
Scand J Gastroenterol; 2010 Dec; 45(12):1397-403. PubMed ID: 20626305
[TBL] [Abstract][Full Text] [Related]
9. Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies.
Tran KT; McMenamin ÚC; Hicks B; Murchie P; Thrift AP; Coleman HG; Iversen L; Johnston BT; Lee AJ; Cardwell CR
Aliment Pharmacol Ther; 2018 Jul; 48(1):55-64. PubMed ID: 29741272
[TBL] [Abstract][Full Text] [Related]
10. Low-Dose Aspirin Use Does Not Increase Survival in 2 Independent Population-Based Cohorts of Patients With Esophageal or Gastric Cancer.
Spence AD; Busby J; Johnston BT; Baron JA; Hughes CM; Coleman HG; Cardwell CR
Gastroenterology; 2018 Mar; 154(4):849-860.e1. PubMed ID: 29122547
[TBL] [Abstract][Full Text] [Related]
11. Statin use and risk of liver cancer: Evidence from two population-based studies.
Tran KT; McMenamin ÚC; Coleman HG; Cardwell CR; Murchie P; Iversen L; Lee AJ; Thrift AP
Int J Cancer; 2020 Mar; 146(5):1250-1260. PubMed ID: 31112291
[TBL] [Abstract][Full Text] [Related]
12. Use of proton pump inhibitors and histamine-2 receptor antagonists and risk of gastric cancer in two population-based studies.
Liu P; McMenamin ÚC; Johnston BT; Murchie P; Iversen L; Lee AJ; Vissers PAJ; Cardwell CR
Br J Cancer; 2020 Jul; 123(2):307-315. PubMed ID: 32367073
[TBL] [Abstract][Full Text] [Related]
13. Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma.
Lagergren J; Bergström R; Adami HO; Nyrén O
Ann Intern Med; 2000 Aug; 133(3):165-75. PubMed ID: 10906830
[TBL] [Abstract][Full Text] [Related]
14. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK.
García Rodríguez LA; Lagergren J; Lindblad M
Gut; 2006 Nov; 55(11):1538-44. PubMed ID: 16785284
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin receptor blocker use and gastro-oesophageal cancer survival: a population-based cohort study.
Busby J; McMenamin Ú; Spence A; Johnston BT; Hughes C; Cardwell CR
Aliment Pharmacol Ther; 2018 Jan; 47(2):279-288. PubMed ID: 29105106
[TBL] [Abstract][Full Text] [Related]
16. Low-dose aspirin and risk of gastric and oesophageal cancer: A population-based study in the United Kingdom using The Health Improvement Network.
García Rodríguez LA; Soriano-Gabarró M; Vora P; Cea Soriano L
Int J Cancer; 2020 Nov; 147(9):2394-2404. PubMed ID: 32329063
[TBL] [Abstract][Full Text] [Related]
17. Exposure to weak opioids and risk of gastrointestinal tract cancers: A series of nested case-control studies.
Houston MG; McMenamin Ú; Johnston B; McDowell RD; Hughes CM; Murchie P; Cardwell CR
Br J Clin Pharmacol; 2023 Sep; 89(9):2757-2766. PubMed ID: 37117154
[TBL] [Abstract][Full Text] [Related]
18. Effects of β2-Adrenergic Agonists on Risk of Parkinson's Disease in COPD: A Population-Based Study.
Chen W; Sadatsafavi M; Tavakoli H; Samii A; Etminan M
Pharmacotherapy; 2020 May; 40(5):408-415. PubMed ID: 32145705
[TBL] [Abstract][Full Text] [Related]
19. Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk?
Lagergren J
Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i1-5. PubMed ID: 15711002
[TBL] [Abstract][Full Text] [Related]
20. Menopausal hormone therapy and risk of oesophageal adenocarcinoma in a population-based cohort study.
Xie SH; Santoni G; Lagergren J
Br J Cancer; 2022 Jan; 126(1):129-133. PubMed ID: 34671128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
